Healthcare dealmaking and capital raising surged across biotechnology, real estate, and artificial intelligence. Electra Therapeutics raised $350 million in a Nasdaq IPO, while Roche entered a $1 billion bispecific antibody partnership with Dualitas Therapeutics. Additionally, CareTrust REIT expanded its holdings with a $400 million nursing home portfolio acquisition.
01Company specific
Electra Raises $350 Million in Initial Public Offering
Funding ipsoprubart's late-stage trial via an offering shifts Electra's clinical execution risk for secondary hemophagocytic lymphohistiocytosis directly onto public equity investors.
Electra Therapeutics raised $350 million in an initial public offering on , pricing the debut to fund its transition into a commercial biotech. The rare disease drugmaker will direct the proceeds toward a registrational trial for its lead experimental drug, ipsoprubart, which targets secondary hemophagocytic lymphohistiocytosis. Electra expects to complete enrollment for the trial in the second half of 2027. The offering makes Electra the 21st biotechnology company to price a new stock issuance in 2026. The listing follows a $183 million venture funding round secured last year from backers including Nextech Invest and EQT Life Sciences.
CareTrust REIT Acquires Southwest Nursing Home Portfolio for $400 Million
Using forward equity settlements and joint ventures to expand triple-net leases with familiar operators lets healthcare REITs scale accretive yield without diluting leverage metrics.
CareTrust closed on a $400 million skilled nursing in the Southwest, pushing its total 2026 investments past $1.9 billion. The transaction covers 2,622 licensed beds structured through a joint venture where CareTrust deployed roughly $380 million of its own , with the facilities triple-net leased back to the existing operator. Management expects the portfolio to generate a stabilized of approximately 8.6 percent, matching the blended 8.7 percent yield across two dozen deals closed this year. Funding came from cash on hand and proceeds from settled forward contracts, leaving the company with $439 million in expected net proceeds from unsettled forwards, $612 million in at-the-market capacity, and $725 million available under its revolving credit facility. Alongside the , CareTrust reported a reloaded investment pipeline of $600 million in near-term opportunities.
Rare EGFR Mutation Found to Significantly Increase Lung Cancer Risk in Never Smokers
Inherited EGFR variants shift lung cancer diagnostics from lifestyle risk factors to genomic screening, expanding the addressable patient population for targeted tyrosine kinase inhibitors.
A rare inherited germline mutation in the epidermal growth factor receptor increases lung cancer risk 62 times in never-smokers and 25 times in smokers, according to a study published in Science. Researchers evaluated genotyping data across 3.37 million individuals from 23andMe to identify the T790M variant, finding its prevalence to be 1 in 15,850. The variant traces back to southern Appalachian populations in the United States and showed a strong association exclusively with lung cancer among 17 conditions screened. Current screening protocols rely solely on tobacco exposure, which on its own increases the risk of developing lung cancer 4 times in the general population. The findings suggest that genetically susceptible individuals might benefit from targeted screening and early detection strategies. AstraZeneca and Johnson and Johnson currently market therapies targeting EGFR-mutated lung cancer, while newer entrants like BlossomHill continue to develop competing molecules.
North Immunology goes public via reverse merger with Aethlon
Securing years of runway via a reverse merger allows a clinical-stage biotech to bypass a sluggish IPO market and fund dual-cytokine antibody trials through mid-stage readouts.
North Immunology is going public through a reverse with Aethlon Medical alongside a $180 million private placement. Existing North Immunology investors will own 95.25% of the combined entity, leaving Aethlon shareholders with the remainder. The newly formed company will operate as North Immunology and trade on the under the ticker symbol NRTX. Funding from the private placement, backed by Bain , Janus Henderson, and Deep Track Capital, is expected to finance operations into the second half of 2028. The company will focus on advancing its lead , NOR-101, a dual-acting antibody targeting IL-13 and IL-18 for the treatment of atopic dermatitis. A Phase 1a clinical study for the drug is scheduled to begin in the first quarter of next year.
Healthcare Agentic AI Adoption Outpacing Governance Frameworks, Report Finds
Shadow deployment of autonomous clinical agents converts software productivity thesis into direct operational liability, exposing healthcare providers to ununderwritten regulatory and malpractice risks.
Healthcare organizations are rapidly adopting agentic while governance frameworks lag behind, according to a report from healthcaredive.com. More than a quarter of leaders have implemented agentic AI, 44% are running pilot or proof-of-concept projects, and 21% plan to deploy the technology within the next year. Over 85% of AI strategy leaders express confidence in their ability to govern autonomous agents, yet 72% of respondents admit that AI tools are deployed without IT approval at least occasionally. Wolters Kluwer data cited in the report shows that 40% of medical workers and administrators know colleagues using unauthorized AI tools, while nearly 20% report using unsanctioned tools themselves. Unchecked agentic AI risks exposing sensitive patient data, entering incorrect medical records, or altering dosages without clinician intent.
Healthcare Agentic AI Adoption Status (%)
Over a quarter of healthcare leaders have already implemented agentic AI.
Roche Partners With Dualitas to Develop Bispecific Immunology Drugs
Structuring deals to retain unselected bispecific antibodies allows early-stage platform biotechs to monetize high-throughput screening for major partners without surrendering their core internal pipeline.
Roche is paying $36.5 million up front to partner with startup Dualitas Therapeutics in a research deal worth up to $1 billion. Dualitas will screen over 300,000 potential bispecific antibody combinations to identify experimental treatments for immune diseases. Dualitas is also eligible for future sales royalties if milestone targets are met. Roche will select a limited number of programs to advance, leaving Dualitas free to develop any skipped programs independently. Dualitas currently advances three internal bispecific antibodies, led by a rheumatoid arthritis program codenamed DTX-102 that is expected to enter the clinic in 2027.
ACORE asserts control over Hell's Kitchen life sciences facility site
Converting stalled ground-up life science projects via deed in lieu transfers pre-development execution risk to lenders when marketwide leasing velocity collapses before vertical construction begins.
Commercialobserver.com reports that Acore has reclaimed the keys to a planned life sciences facility site in Hell's Kitchen through a $60 million deed in lieu of . The lender seized the properties at 707 11th Avenue and 615 West 50th Street after developers Georgetown Company and Beacon Capital Partners fell behind on . Georgetown and Beacon had acquired the buildings for $95 million in 2021 with intentions to build Manhattan's first ground-up, purpose-built life science property in a decade. Plans filed in early 2023 to replace the former Kenneth Cole headquarters with a seven-story research facility stalled during pre-development. ACORE filed a pre-foreclosure action in April before taking ownership through the Wexford Investment Trust entity. Post-pandemic vacancies continue to pressure the sector, with Manhattan leasing volume dropping 84 percent in the first quarter of 2026.
Substantial private placements, IPOs, and billion-dollar partnerships show investors are eagerly deploying capital across healthcare sectors. Yet widespread unapproved agentic AI usage and defaulted real estate projects reveal operational risks that could trigger regulatory backlash or financial strain.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.